XIDX
DVLA
Market cap103mUSD
Nov 12, Last price
1,655.00IDR
Name
Darya-Varia Laboratoria Tbk PT
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
PT Darya-Varia Laboratoria Tbk is an Indonesian enterprise dedicated to the production and commercialization of pharmaceutical goods and cosmetic items. Its operations are organized into three primary divisions: prescription medications, consumer health products, and services for export and contract manufacturing. The company offers a comprehensive selection of both prescribed and over-the-counter health solutions, addressing categories like antibiotics, antiparasitics, antiseptics, antifungals, treatments for coughs and colds, cardiovascular conditions, central nervous system disorders, gastrointestinal and liver ailments, somatic issues, vitamins and dietary supplements, women's health, ear care, and dermatological concerns. Beyond its domestic activities, the firm also distributes its products internationally to nations such as Malaysia, Myanmar, the Philippines, Singapore, Vietnam, and Mongolia. Established in 1976, PT Darya-Varia Laboratoria Tbk is headquartered in Jakarta, Indonesia, and functions as a subsidiary of Blue Sphere Singapore Pte. Ltd.
Key people
Clinton Andrew Hess
President Commissioner · since 2019
Jose Sumpaico Romana
President Director · since 2020
Eric Albert Gotuaco
Vice President Commissioner · since 2019
Ian Kloer
Vice President Director · since 2020
Maria Christina Carnay
Director · since 2020
Carlos Nava
Director · since 2009
Angelito Celso Racho
Director · since 2010
Yustina Endang Setyowati
Independent Director · since 2017
Widya Olivia Tobing
Corporate Secretary · since 2017
Marlia Hayati Goestam
Commissioner · since 2020
Mariano John Tan
Commissioner · since 2010
Sancoyo Antarikso
Independent Commissioner · since 2021
Sonny Kalona
Independent Commissioner · since 2010
Valuation
Title IDR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||